Sickle Cell Treatment Market is Segmented By Treatment(Surgical Procedures, Blood Transfusion, Bone Marrow Transplant, Others), By Medication(Hydroxyurea (Droxia, Hydrea, Siklos), L-glutamine oral powder (Endari), Crizanlizumab (Adakveo), Voxelotor (Oxbryta)) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Sickle Cell Treatment Overview
Sickle Cell Treatment Market is estimated to reach at a CAGR of 18.5% during the forecast period (2024-2031).
Sickle cell anemia management is usually aimed at preventing complications, relieving symptoms, and avoiding pain episodes. Treatments might include blood transfusions and medications. A stem cell transplant might cure the disease in some children and teenagers.
Sickle Cell Treatment Market Scope and Summary
| Metrics | Details |
| Market CAGR | 18.5% |
| Segments Covered | By Treatment, By Medication, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Download Sample
Sickle Cell Treatment Market Dynamics
The increasing incidence rate of sickle cell anemia and rising research is expected to drive the global sickle cell treatment market.
Increasing research is expected to drive the global sickle cell treatment market in the forecast period.
An inherited blood disorder, sickle cell disease (SCD), can cause anemia, infection, pain, and other serious health problems. CDC leads finding out SCD monitoring or the number of people with this disorder and how it affects their health. This information helps health care providers and researchers improve the health of people with SCD. In some patient's bone marrow transplants can cure sickle cell disease. Research has advanced on the condition of other areas of medicine, including molecular biology and genetics. Researchers have learned that periodic blood transfusions in children at high risk of stroke help reduce the risk of having a first stroke.
Worldwide for the millions of people who have sickle cell disease, only a few treatment options, including risky bone marrow transplants, address a subset of symptoms. For instance, by boosting fetal hemoglobin levels in recent times, researchers describe the discovery of a small molecule with the need to address the root cause of sickle cell disease.
Side effects associated with sickle cell treatment are expected to hamper market growth.
Usually, around five months of age, people with sickle cell disease (SCD) tend to show symptoms of the disease during the first year of life. Signs and complications of SCD are different for each person and can range from mild to severe. Infants don't show symptoms at birth because the fetal or baby hemoglobin protects red blood cells from sickling. The baby's or fetal around 4 to 5 months of age hemoglobin is replaced by sickle hemoglobin, and the cells begin to sickle. Sickle cell disease worsens over time.
Several complications of SCD can be decreased by hydroxyurea medicine. This treatment is safe when given by medical specialists. However, the side effects of hydroxyurea for a long time or during pregnancy are not known completely. Another treatment that can cure sickle cell disease is a stem cell transplant (also called a bone marrow transplant). Although transplants of blood or bone marrow from healthy donors are increasingly being used to cure SCD successfully, they require a matched donor (a person with similar, compatible bone marrow), and transplants can sometimes cause severe side effects, including rare, life-threatening illness or death. People with SCD and their families should ask their doctors about the benefits and risks of each treatment option.
Sickle Cell Treatment Market Industry Analysis
COVID-19 Impact Analysis
The healthcare industry has been affected by COVID-19. COVID-19 had a mixed impact on the market. Many surgeries were put on hold. The postponement surgeries resulted in a decrease in BMT blood transfusion procedures. For instance, according to American Red Cross, As the Delta variant spread, blood centers across the country reported a shortage of blood supplies. Because of the recent COVID-19 case surge and the busy back-to-school season, some blood collection organizations are seeing an unusual drop in donor turnout; others are seeing blood drive cancellations at schools and businesses, limiting the number of people allowed on site as a precautionary pandemic practice.
Sickle Cell Treatment Market Segment Analysis
The blood transfusion segment is expected to dominate the global sickle cell treatment market.
Leading to abnormal hemoglobin, sickle cell disease is caused by a genetic mutation known as sickle hemoglobin. By lowering the oxygen-carrying capacity of the blood, sickle hemoglobin binds less oxygen than usual. It also leads to sickle-shaped red blood cells, which interfere with blood flow and increase the blood's viscosity (thickness and stickiness).
Via intravenous injection, a blood transfusion provides a person with donated blood. Through this procedure, different blood components can be delivered. Normal red blood cells are provided to the patient's body through blood transfusion in patients with sickle cell disease. Red blood cell transfusions help decrease anemia and reduce the blood's viscosity, allowing it to flow more freely, ease disease symptoms, and prevent complications. It's difficult in sickle cell patients to increase the oxygen-carrying capacity of red blood cells. For instance, parvovirus B19 infection can decrease the production of new red blood cells or erythropoiesis. Since they have reduced oxygen-binding capacity and have a short lifespan than normal red blood cells, this infection can be dangerous for these patients. In such instances, a red blood cell transfusion can be lifesaving.
The specialty clinics segment is expected to dominate the global sickle cell treatment market in the forecast period.
According to the National Institutes of Health, the optimal care for patients with sickle cell disease is best treated in clinics that specialize in sickle cell disease care. All patients should have a principal health care provider, who should either be a hematologist or be in frequent consultation with one.
In episodes of more severe anemia, doctors may use blood transfusions to boost normal red blood cells in children with sickle cell disease. As transfusions increase the number of normal red blood cells, they can help alleviate complications, such as acute chest syndrome. When used as a long-term therapy, reducing the number of abnormal red blood cells prevents the occurrence of a stroke which can cause a stroke and narrow blood vessels.
Sickle Cell Treatment Market Geographical Share
North America region is expected to dominate the global sickle cell treatment market.
The increasing prevalence of Sickle Cell disease in this is expected to fuel the market growth. For instance, approximately SCD affects 100,000 Americans. SCD occurs among about 1 out of every 365 Black or African American births. It occurs among about 1 out of every 16,300 Hispanic-American births. About 1 in 13 African or Black American babies is born with sickle cell trait (SCT). The US FDA granted accelerated approval to Oxbryta (voxelotor) to treat sickle cell disease in pediatric and adults patients 12 years of age and older. In the U.S.the, support provides additional hope to the 100,000 people, and globally more than 20 million, who live with this debilitating blood disorder.
The US FDA approved a treatment to reduce the frequency of vaso-occlusive crisis Adakveo (crizanlizumab-tmca), a painful and common complication of sickle cell disease for patients aged 16 years older when blood circulation is obstructed by sickled red blood cells. Hence, this region is expected to dominate the global market for sickle cell treatment.
Sickle Cell Treatment Market Companies and Competitive Landscape
The global sickle cell treatment market is highly competitive with increasing demand for its treatment, company mergers, and the development of treatment options.
Major key players in global sickle cell treatment are Novartis AG, Pfizer Inc., bluebird bio-Inc., global blood therapeutics Inc., Sangamo Therapeutics, Inc., F. Hoffmann-La Roche AG, Emmaus Life Sciences; Inc., Bristol-Myers Squibb, CRISPR Therapeutics.
Novartis AG
Overview: Novartis International AG is a Swiss-American pharmaceutical corporation with headquarters in Basel, Switzerland, and Cambridge, Massachusetts, in the United States. The company was founded in 1996.
Product Portfolio: The company's Adakveo drug can be used as an adjunct to hydroxyurea/hydroxycarbamide (HU/HC) therapy or as a stand-alone therapy in patients for whom HU/HC is inappropriate or insufficient. And the drug has been approved for pain crisis in patients with sickle cell disease; Adakveo binds to P-selectin, a cell adhesion protein that is important in the multicellular interactions that can result in vaso-occlusion.
Critical Development: On 15 November 2019, the US Food and Drug Administration (FDA) approved Novartis, previously known as SEG101, Adakveo (crizanlizumab) drug to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult and pediatric patients aged 16 years and older with sickle cell disease.
